All articles by Molly Lempriere

Betting big on Gamma Delta T Cells

Until recently, Gamma Delta T Cells, which live in our tissue and form a crucial part of our immune system,…
Reforming paediatric cancer trials in Europe

Cancer experts are calling on European officials to reform outdated rules on clinical trials that allow pharmaceutical companies to opt…
Could a temperature-resistant vaccine spell the end for rabies and yellow fever?

Rabies and yellow fever claim tens of thousands of lives every year and although vaccines do exist, they are either…
Cancergraph: a desperately needed link between patient and clinical trial

Clinical trial recruitment can be notoriously challenging. For the pharma company, it can be tough to find patients that meet…
Medicines Discovery Catapult: improving collaborative drug discovery in the UK

Drug discovery is a notoriously expensive and time-consuming process, with many potential stumbling blocks on the path from research lab…

Why the UK NHS needs clinical research

In October last year, the National Institute for Health Research (NIHR) made a welcome announcement – for the first time,…
Pay-for-delay: how far will companies go to protect market exclusivity?

Pay-for-delay agreements, or reverse payment patent settlements, have been under scrutiny for a while. In essence, these deals allow large…
Genomic array could unlock war against diseases in Africa

A new cost-effective array designed specifically to study African populations will offer researchers unprecedented insight into the genomic and environmental…
Developing new drugs for Tourette syndrome

Despite being a relatively common condition, Tourette syndrome (TS) is widely misunderstood. Affecting as many as one in every one…